Incyte (NASDAQ:INCY) stock was trading in the red premarket on Tuesday after Q1 results missed estimates, but the company tightened its 2023 net product revenues outlook for bone marrow cancer drug Jakafi.
Incyte (NASDAQ:INCY) stock was trading in the red premarket on Tuesday after Q1 results missed estimates, but the company tightened its 2023 net product revenues outlook for bone marrow cancer drug Jakafi.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.